It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Transient receptor potential vanilloid 2 (TRPV2) is involved in many critical physiological and pathophysiological processes, making it a promising drug target. Here we present cryo-electron microscopy (cryo-EM) structures of rat TRPV2 in lipid nanodiscs activated by 2-aminoethoxydiphenyl borate (2-APB) and propose a TRPV2-specific 2-ABP binding site at the interface of S5 of one monomer and the S4-S5 linker of the adjacent monomer. In silico docking and electrophysiological studies confirm the key role of His521 and Arg539 in 2-APB activation of TRPV2. Additionally, electrophysiological experiments show that the combination of 2-APB and cannabidiol has a synergetic effect on TRPV2 activation, and cryo-EM structures demonstrate that both drugs were able to bind simultaneously. Together, our cryo-EM structures represent multiple functional states of the channel, providing a native picture of TRPV2 activation by small molecules and a structural framework for the development of TRPV2-specific activators.
A non-selective calcium channel transient receptor potential vanilloid 2 (TRPV2) is a potential drug target. Here, the authors employ cryo-electron microscopy, in silico docking, and electrophysiology to identify a binding site for an activator 2-aminoethoxydiphenyl borate (2-APB) in this channel.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, Philadelphia, United States (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
2 Hannover Medical School, Department of Anesthesiology and Intensive Care Medicine, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
3 University of California, Department of Physiology and Membrane Biology, Davis, United States (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684)
4 Universidade de Lisboa, Instituto de Medicina Molecular, Faculdade de Medicina, Lisboa, Portugal (GRID:grid.9983.b) (ISNI:0000 0001 2181 4263)
5 Universidade de Lisboa, Instituto de Medicina Molecular, Faculdade de Medicina, Lisboa, Portugal (GRID:grid.9983.b) (ISNI:0000 0001 2181 4263); University of Cambridge, Department of Chemistry, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)